At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Tanguy Seiwert, MD, from The University of Chicago Medicine, Chicago, IL, discusses the clinical development of immune checkpoint inhibitors, including pembrolizumab, an anti-PD-1 antibody, and durvalumab, an anti-PD-L1 antibody, for the treatment of patients with head and neck cancer.
Therapeutic advances in immune checkpoint inhibitors for head and neck cancers
5th February 2016
Join our mailing list
To receive the EMJ updates straight to your inbox free of charge, please click the button below.Join Now